This Special Interest Group (SIG) was created to address a major gap in clinical trial design for epilepsy: the lack of standardized and meaningful measures of seizure severity. While most trials rely on seizure frequency as the primary outcome, this does not adequately capture the real-life impact of epilepsy on patients’ quality of life.
Current Activities
If you are interested to voluntarily contribute to this SIG activities, please use the contact form to let us know.